Trial Outcomes & Findings for Young Blind Child Melatonin Treatment Study (NCT NCT00688935)
NCT ID: NCT00688935
Last Updated: 2019-11-27
Results Overview
TERMINATED
NA
9 participants
every 2-4 weeks throughout the entire study
2019-11-27
Participant Flow
The PI has retired from the institution. Sincere efforts were made to contact the PI/study team members, but were unsuccessful. No study data are available.
Participant milestones
| Measure |
Melatonin
Subjects may opt to enroll in this treatment sub-study involving melatonin treatment (0.1 - 3 mg, daily) for up to 1 year, with a minimum of 6 weeks. Throughout treatment, subjects will continue their saliva, plasma, and/or urine sampling to test for treatment efficacy.
Melatonin: 0.1-3 mg, daily, up to 1 year (minimum duration of 6 weeks)
|
|---|---|
|
Overall Study
STARTED
|
0
|
|
Overall Study
COMPLETED
|
0
|
|
Overall Study
NOT COMPLETED
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Young Blind Child Melatonin Treatment Study
Baseline characteristics by cohort
Baseline data not reported
PRIMARY outcome
Timeframe: every 2-4 weeks throughout the entire studyPopulation: The PI has retired from the institution. Sincere efforts were made to contact the PI/study team members, but were unsuccessful. No study data are available.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: 1 12-hour assessment any time during the studyPopulation: The PI has retired from the institution. Sincere efforts were made to contact the PI/study team members, but were unsuccessful. No study data are available.
Outcome measures
Outcome data not reported
Adverse Events
Melatonin
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
OHSU Integrity Department
Oregon Health and Science University
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place